NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

Paul Theisen
Patient Acquisition

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment